ClinicalTrials.gg
CompletedNCT02127034Updated Jul 11, 2014

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

A Phase 1 interventional study of Mirabegron and Solifenacin in Healthy Subjects, Pharmacokinetics and Drug-Drug Interaction (DDI), sponsored by Astellas Pharma Europe B.V.. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-11.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of steady state solifenacin and mirabegron on the pharmacokinetics of co-administered steady state digoxin. This study will also evaluate the safety and tolerability of the combined steady state administration of solifenacin, mirabegron and digoxin.

Read the detailed description

This study is comprised of two study sequences with 2 investigational periods in each sequence. There will be a wash-out period between each investigational period. Patients will be admitted to the clinic until discharged after each investigational period.

02

Conditions studied

  • Healthy Subjects
  • Pharmacokinetics
  • Drug-Drug Interaction (DDI)

Keywords

  • Healthy subjects
  • Mirabegron
  • Solifenacin
  • Digoxin
03

In context

Lead sponsor

Astellas Pharma Europe B.V. is the lead sponsor of 94 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a range of 20.0 to 30.0 kg/m2, inclusive. The subject weighs at least 50 kg [screening].
  • Female subject must either:

    • Be of non-child bearing potential:

      1. (defined as at least 1 year without any menses) prior to screening, or
      2. documented surgically sterile
    • Or, if of ,

      1. Agree not to try to become pregnant during the clinical study and for 28 days after the final study drug administration, and
      2. must have a negative urine/serum pregnancy test at screening and day -1,and
      3. if heterosexually active, agree to consistently use 2 forms of highly effective starting at screening and throughout the clinical study period and for 28 days after the final study drug administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the clinical study period, and for 28 days after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the clinical study period, and for 28 days after the final study drug administration.
  • Male subject and their female spouse/partners who are of childbearing potential must be using a highly effective form of contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the clinical study period and for 90 days after the final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the clinical study period and for 90 days after the final study drug administration
  • Subject agrees not to participate in another interventional study while participating in the present clinical study, defined as signing the form (ICF) until completion of the last study visit.

Exclusion criteria

Exclusion Criteria:

  • Female subject who has been pregnant within 6 months prior to screening assessment or breast feeding within 3 months prior to screening.
  • Subject has a known or suspected to solifenacin succinate, mirabegron, digoxin or any components of the formulations used.
  • Subject has any of the liver function tests (LFTs) ( [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], GGT, total [TBL]) above the (ULN). In such a case the assessment may be repeated once [day -1].
  • Subject has any history of allergic conditions.
  • Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to day -1.
  • Subject has any clinically significant abnormality following the Investigator's review of the physical examination, (e.g., any level of sinus node disease or atrioventricular defect) and protocol defined clinical laboratory tests (e.g., electrolyte abnormalities such as hypokalemia) at screening or day -1.
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or , as judged by the medical Investigator.
  • Subject has a mean heart rate (HR) of \< 50 or > 90 beats per minute (bpm); mean systolic BP >140 mmHg; mean diastolic BP > 90 mmHg at day-1 (vital sign measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically).
  • Subject has a mean (F) interval of > 430 ms (for males) and > 450 ms (for females) at day-1. If the mean QTc(F) exceeds the limits above, 1 additional triplicate ECG can be taken. If this triplicate also gives abnormal result the subject should be excluded.
  • Subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsade de pointes, structural heart disease, or a family history of Long QT Syndrome.
  • Subject has any clinically significant history of or risk of urinary retention, severe gastrointestinal condition (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma.
  • Subject uses any prescribed or non-prescribed drugs (including vitamins, hormone replacement therapy or natural and herbal remedies [e.g., St. John's Wort]) in the 2 weeks prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day).
  • Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.
  • Subject has a history of drinking more than 21 units (14 units for females) of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit.
  • Subject consumes grapefruit juice (more than 3 x 200 mL) or marmalade (more than 3 times) star fruit, Seville oranges or Seville orange juice containing products in the week prior to admission to the clinical unit until end of study visit (ESV), as reported by the subject.
  • Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit.
  • Subject regularly uses of any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit.
  • Subject has significant blood loss, donated 1 unit (500 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission on day -1.
  • Subject has a positive serology test for surface antigen (HBsAg), hepatitis B core (HBc) antibodies, hepatitis A virus (HAV) antibodies (Immunoglobulin M [IgM]), virus (HCV) antibodies or (HIV) 1+2 antibodies.
  • Subject participated in any clinical study or has been treated with any drugs within 28 days prior to screening.
  • Subject is a vulnerable subject (e.g., subject kept in detention).
  • Subject is an employee of the Astellas Group or Contract Research Organization (CRO) involved in the clinical study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Digoxin / digoxin + solifenacin and mirabegron

    Digoxin alone then followed by digoxin with solifenacin and mirabegron

    Drug: Mirabegron · Drug: Solifenacin · Drug: Digoxin

  • Experimental
    Digoxin + solifenacin and mirabegron / digoxin

    Digoxin with solifenacin and mirabegron then followed by digoxin alone

    Drug: Mirabegron · Drug: Solifenacin · Drug: Digoxin

Interventions

  • oral

    Also known as: Myrbetriq, Betmiga, Betamis

  • oral

    Also known as: solifenacin succinate, Vesikur, Vesicare

  • oral

    Also known as: Lenoxin

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter for digoxin (plasma) in the absence and presence of solifenacin and mirabegron: Cmax

    Maximum concentration (Cmax)

    Time frame: Day 10

  2. Pharmacokinetic parameter for digoxin (plasma) in the absence and presence of solifenacin and mirabegron: AUCtau

    Area under the curve over a dosing interval (AUCtau)

    Time frame: Day 10

Secondary outcomes

  1. Pharmacokinetic parameter for digoxin (plasma): Ctrough

    Concentration immediately prior to dosing at multiple dosing (Ctrough)

    Time frame: Days 7, 8 and 9 in each investigational period

  2. Pharmacokinetic parameter for digoxin (plasma): tmax, CL/F, PTR

    Time after dosing when Cmax occurs (tmax), apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F), Peak-through ratio (PTR)

    Time frame: Days 10 in each investigational period

  3. Pharmacokinetic parameter for digoxin (urine): Aetau, CLR, Aetau%

    Cumulative amount of drug excreted into urine, feces or bile from the time of dosing to the start of the next dosing interval (Aetau), renal clearance (CLR), percent of drug dose excreted into urine, feces or bile (Aetau) over the time interval between consecutive dosing (Aetau%)

    Time frame: Day 10 in each investigational period

  4. Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Ctrough

    Concentration immediately prior to dosing at multiple dosing (Ctrough)

    Time frame: Days 7, 8 and 9 (1 investigational period per sequence only)

  5. Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Cmax, AUCtau, tmax, CL/F

    Maximum concentration (Cmax), Area under the curve over a dosing interval (AUCtau), Time after dosing when Cmax occurs (tmax), apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)

    Time frame: Day 10 (1 investigational period per sequence only)

  6. Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Cpredose

    Concentration immediately prior to the first dose (Cpredose)

    Time frame: Day 1 (1 investigational period for only 1 treatment sequence)

  7. Genotyping for CYP2D6

    Time frame: Day 1

  8. Safety as assessed by adverse events, physical examination, vital signs, 12-lead ECG and laboratory tests

    Time frame: Up to Day 11 in each investigational period (and at end of study visit, up to 9 days after)

07

Study locations

1 site
  • Parexel International GmbH
    Berlin, 14050, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2014
First posted
Apr 30, 2014
Start
Mar 2014
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Jul 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02127034
Responsible party
Sponsor
First posted
Apr 30, 2014
Start date
Mar 2014
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Jul 11, 2014

Study contacts

Clinical Research Physician
study director · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mirabegron · Solifenacin · Digoxin

Start the discussion